Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock Oppenheimer has initiated coverage on Larimar Therapeutics ...

BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share.

In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a ...

For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...

Nov 6 (Reuters) - Industrial software maker PTC (PTC.O), opens new tab forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design ...

Engineering and design software provider PTC (NASDAQ:PTC) will be reporting results tomorrow afternoon. Here’s what to look for. PTC missed analysts’ revenue expectations by 2.8% last quarter ...

In other PTC news, Director Janice Chaffin sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $171.34 ...

PTC Therapeutics, Inc. (PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization continues the process initiated in ...

PTC Forecasts Quarterly Revenue Below Estimates on Tight Tech Spending (Reuters) - Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued ...

(Reuters) -Royalty Pharma said on Thursday it has purchased additional royalties on Roche and PTC Therapeutics (NASDAQ:PTCT)' oral spinal muscular atrophy (SMA) drug for an ...